Mitsui Chemicals Backs iORGANBIO Cell Platform
Japan's Mitsui Chemicals has invested in Morrisville, North Carolina-based iORGANBIO to combine technologies for producing human cells and organoids.
Updated on Nov. 10, 2026 in Biotech
Mitsui Chemicals invested in iORGANBIO through its 321Catalyst corporate venture capital fund, and the two companies will combine their technologies to improve human cell and organoid production. iORGANBIO's platform integrates AI, single-cell analysis and robotics into a closed-loop autonomous laboratory.
Why it matters
The partnership aims to enable production of cell types and organoids that have previously been difficult to manufacture. The companies also plan to explore drug discovery technologies that could complement or serve as alternatives to animal testing.
The announcement was made November 10, 2026, roughly two years after iORGANBIO was founded in July 2024. The investment amount and collaboration terms were not disclosed.
The players
iORGANBIO
A Morrisville, North Carolina company developing an AI-driven, closed-loop autonomous laboratory platform for producing human cells and organoids, led by CEO Daniel Delubac.
Mitsui Chemicals
A Japanese chemical company listed on the Tokyo Stock Exchange under code 4183 that invests through its 321Catalyst corporate venture capital fund.
The details
iORGANBIO's proprietary platform produces target cells with a high degree of uniformity and reproducibility. Mitsui Chemicals contributes materials design capabilities, including its InnoCell cell culture plates, to optimize culture conditions that allow cells to grow and function consistently.
Timeline
July 2024: iORGANBIO is founded.
November 10, 2026: The investment and collaboration are announced.
Roadmap
Organoids grown from human cells have become a growing alternative to animal models in drug development. This investment extends that approach by targeting cell types that have historically been difficult to produce at scale.
For patients and consumers, this work is a longer-term development rather than an immediate change. Improved cell and organoid production could eventually influence which drugs reach people and how they are tested before approval.
The takeaway
Investment from established chemical companies into early-stage biotech platforms can signal confidence in technologies aimed at replacing or reducing animal testing. Readers tracking drug development should watch whether such partnerships produce published results.
Further reading
For more on regional research activity, explore Biotech coverage across North Carolina.
Source note: This article includes information reported by The Manila times.
